Spruce Biosciences, Inc.

Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

Spruce Biosciences to Present at Upcoming Investor Conferences in March

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference